Orexo AB

Suède

Retour au propriétaire

1-83 de 83 pour Orexo AB et 1 filiale Trier par
Recheche Texte
Affiner par
Type PI
        Brevet 48
        Marque 35
Juridiction
        International 31
        États-Unis 29
        Canada 13
        Europe 10
Propriétaire / Filiale
[Owner] Orexo AB 82
PharmaKodex Limited 1
Date
Nouveautés (dernières 4 semaines) 2
2026 mai (MACJ) 1
2026 mars 1
2026 février 1
2026 (AACJ) 4
Voir plus
Classe IPC
A61K 9/16 - AgglomérésGranulésMicrobilles 34
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier 31
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine 15
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine 13
A61M 15/08 - Dispositifs d'inhalation placés dans le nez 9
Voir plus
Classe NICE
05 - Produits pharmaceutiques, vétérinaires et hygièniques 18
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture. 17
42 - Services scientifiques, technologiques et industriels, recherche et conception 16
41 - Éducation, divertissements, activités sportives et culturelles 12
09 - Appareils et instruments scientifiques et électriques 10
Voir plus
Statut
En Instance 15
Enregistré / En vigueur 68

1.

NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY

      
Numéro d'application 19234579
Statut En instance
Date de dépôt 2025-06-11
Date de la première publication 2026-05-07
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert
  • Fischer, Andreas

Abrégé

According to the invention, there is provided a pharmaceutically-acceptable composition which is preferably in the form of a spray-dried powder comprising a mixture of: (fffffffffffff) a pharmacologically-effective dosage amount of at least one pharmaceutically-active compound; and (ggggggggggggg) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. According to the invention, there is provided a pharmaceutically-acceptable composition which is preferably in the form of a spray-dried powder comprising a mixture of: (fffffffffffff) a pharmacologically-effective dosage amount of at least one pharmaceutically-active compound; and (ggggggggggggg) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Compositions are suitable for, for example, transmucosal drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. cyclodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine

2.

AMORPHOX

      
Numéro d'application 1915687
Statut Enregistrée
Date de dépôt 2026-03-11
Date d'enregistrement 2026-03-11
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Pharmaceutical preparations. Development of pharmaceutical preparations; research and development in the pharmaceutical fields; research and development of drug delivery platforms. Licensing of intellectual property.

3.

AMORPHOX

      
Numéro de série 79449119
Statut En instance
Date de dépôt 2026-03-11
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Pharmaceutical preparations. Development of pharmaceutical preparations; research and development in the pharmaceutical fields; research and development of drug delivery platforms. Licensing of intellectual property.

4.

PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERY

      
Numéro d'application 19361103
Statut En instance
Date de dépôt 2025-10-17
Date de la première publication 2026-02-12
Propriétaire Orexo AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert
  • Fischer, Andreas

Abrégé

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

Classes IPC  ?

  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles

5.

AMORPHOX

      
Numéro d'application 019255186
Statut Enregistrée
Date de dépôt 2025-10-01
Date d'enregistrement 2026-01-18
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Licensing of intellectual property.

6.

NEW PHARMACEUTICAL DEVICE FOR USE IN INTRANASAL ADMINISTRATION

      
Numéro d'application 19189960
Statut En instance
Date de dépôt 2025-04-25
Date de la première publication 2025-08-21
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert

Abrégé

Disclosed is a needle-free applicator that is suitable for administering a solid, amorphous, mono-particulate powder composition into a body cavity of a human patient, which cavity includes a mucosal surface, wherein the applicator comprises: (i) an opaque reservoir comprising said powder composition; (ii) an optional actuating means for generating a force upon actuation of the device by a user; and (iii) a dispensing means through which, following said actuation, said powder composition may be dispensed, wherein said powder composition comprises a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof, encapsulated in an amorphous state along with a pharmaceutically-acceptable carrier material; and which powder composition is less than about 4% chemically degraded after storage for: (a) at least about 3 months at 40° C. and 75% relative humidity; and/or (b) at least about 18 months at below about 30° C.; and/or (c) at least about 18 hours at above about 1 million lux of UV light.

Classes IPC  ?

  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
  • A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine

7.

PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERY

      
Numéro d'application 19076099
Statut En instance
Date de dépôt 2025-03-11
Date de la première publication 2025-06-26
Propriétaire Orexo AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert
  • Fischer, Andreas

Abrégé

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

Classes IPC  ?

  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles

8.

Pharmaceutical composition comprising adrenaline

      
Numéro d'application 18592846
Numéro de brevet 12472154
Statut Délivré - en vigueur
Date de dépôt 2024-03-01
Date de la première publication 2025-02-06
Date d'octroi 2025-11-18
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert

Abrégé

a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.

Classes IPC  ?

  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61M 15/08 - Dispositifs d'inhalation placés dans le nez

9.

PHARMACEUTICAL COMPOSITION COMPRISING BIOPHARMACEUTICAL DRUG COMPOUNDS

      
Numéro d'application 18712027
Statut En instance
Date de dépôt 2022-11-25
Date de la première publication 2024-12-12
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert

Abrégé

According to the invention, there is provided a which composition is in the form of an amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one biopharmaceutical drug compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. maltodextrins). Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Powder compositions may be produced by spray-drying the various components together in combination.

Classes IPC  ?

  • A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
  • A61K 38/43 - EnzymesProenzymesLeurs dérivés
  • A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
  • A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine

10.

VYZYP

      
Numéro de série 98897402
Statut En instance
Date de dépôt 2024-12-11
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Medical preparation for use as a narcotic antagonist in the treatment of narcotic overdose; Drug delivery devices, namely, nasal delivery devices sold filled with pharmaceutical preparations for use in the treatment of narcotic overdose; Pharmaceutical preparations in the form of powders for treatment of opioid addiction and overdose.

11.

IZIPRY

      
Numéro de série 98897408
Statut En instance
Date de dépôt 2024-12-11
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Medical preparation for use as a narcotic antagonist in the treatment of narcotic overdose; Drug delivery devices, namely, nasal delivery devices sold filled with pharmaceutical preparations for use in the treatment of narcotic overdose; Pharmaceutical preparations in the form of powders for treatment of opioid addiction and overdose.

12.

SPRAY-DRIED COMPOSITIONS COMPRISING ADRENERGIC RECEPTOR MODULATORS

      
Numéro de document 03293512
Statut En instance
Date de dépôt 2024-05-31
Date de disponibilité au public 2024-12-05
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Savmarker, Jonas
  • Ronn, Robert

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61P 37/08 - Agents antiallergiques

13.

SPRAY-DRIED COMPOSITIONS COMPRISING CGRP RECEPTOR ANTAGONISTS

      
Numéro d'application GB2024051413
Numéro de publication 2024/246541
Statut Délivré - en vigueur
Date de dépôt 2024-05-31
Date de publication 2024-12-05
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert

Abrégé

According to the invention, there is provided a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of a small molecule CGRP receptor antagonist, or a pharmaceutically-acceptable salt thereof; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for, for example, transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred CGRP receptor antagonists include the gepants, such as ubrogepant, atogepant, rimegepant and zavegepant. The compositions are thus particularly useful in the treatment of migraine related conditions.

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
  • A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
  • A61P 25/06 - Agents antimigraineux

14.

SPRAY-DRIED COMPOSITIONS COMPRISING CGRP RECEPTOR ANTAGONISTS

      
Numéro de document 03293506
Statut En instance
Date de dépôt 2024-05-31
Date de disponibilité au public 2024-12-05
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Savmarker, Jonas
  • Ronn, Robert

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
  • A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
  • A61P 25/06 - Agents antimigraineux

15.

SPRAY-DRIED COMPOSITIONS COMPRISING ADRENERGIC RECEPTOR MODULATORS

      
Numéro d'application GB2024051426
Numéro de publication 2024/246554
Statut Délivré - en vigueur
Date de dépôt 2024-05-31
Date de publication 2024-12-05
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert

Abrégé

According to the invention, there is provided a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin, which solid compositions, when dissolved in aqueous media, exhibit a pH of between about 4.5 and about 8.0. Said compositions are suitable for, for example, transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and the maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61P 37/08 - Agents antiallergiques

16.

Method of controlling depression in subjects treated for opioid dependence

      
Numéro d'application 18194678
Numéro de brevet 12138259
Statut Délivré - en vigueur
Date de dépôt 2023-04-03
Date de la première publication 2024-11-12
Date d'octroi 2024-11-12
Propriétaire OREXO AB (Suède)
Inventeur(s) Sumner, Michael John

Abrégé

The present disclosure is directed to a method of combatting opioid dependence in a subject experiencing a depressive episode. The method comprises treating the subject with an opioid agonist whilst managing their depression or depressive disorder using a step-wise interactive process, particularly where the process involves virtual cognitive behavioral therapy comprising a program for self-treatment. The self-treatment program could be embodied as a mobile medical application.

Classes IPC  ?

  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61P 25/24 - Antidépresseurs
  • A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés

17.

Pharmaceutical composition for nasal delivery

      
Numéro d'application 18542954
Numéro de brevet 12268684
Statut Délivré - en vigueur
Date de dépôt 2023-12-18
Date de la première publication 2024-08-01
Date d'octroi 2025-04-08
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert
  • Fischer, Andreas

Abrégé

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

Classes IPC  ?

  • A61K 31/33 - Composés hétérocycliques
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine

18.

Method of controlling alcohol consumption in subjects treated for opioid dependence

      
Numéro d'application 17363860
Numéro de brevet 11986472
Statut Délivré - en vigueur
Date de dépôt 2021-06-30
Date de la première publication 2024-05-21
Date d'octroi 2024-05-21
Propriétaire OREXO AB (Suède)
Inventeur(s) Sumner, Michael John

Abrégé

The present disclosure is directed to a method of combatting opioid dependence in a subject who is misusing alcohol or susceptible to alcohol misuse. The method comprises treating the subject with an opioid agonist whilst managing their alcohol consumption using a step-wise interactive process, particularly where the process involves virtual cognitive behavioral therapy comprising a program for self-treatment. The self-treatment program could be embodied as a mobile medical application.

Classes IPC  ?

  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène

19.

Pharmaceutical composition for drug delivery

      
Numéro d'application 18345770
Numéro de brevet 12357573
Statut Délivré - en vigueur
Date de dépôt 2023-06-30
Date de la première publication 2024-01-25
Date d'octroi 2025-07-15
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert
  • Fischer, Andreas

Abrégé

(b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Compositions are suitable for, for example, transmucosal drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. cyclodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine

20.

Pharmaceutical composition comprising adrenaline

      
Numéro d'application 18323101
Numéro de brevet 11957647
Statut Délivré - en vigueur
Date de dépôt 2023-05-24
Date de la première publication 2023-11-09
Date d'octroi 2024-04-16
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert

Abrégé

Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.

Classes IPC  ?

  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61M 15/08 - Dispositifs d'inhalation placés dans le nez

21.

Pharmaceutical device for use in intranasal administration

      
Numéro d'application 18323115
Numéro de brevet 12303472
Statut Délivré - en vigueur
Date de dépôt 2023-05-24
Date de la première publication 2023-10-05
Date d'octroi 2025-05-20
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert

Abrégé

(c) at least about 18 hours at above about 1 million lux of UV light.

Classes IPC  ?

  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
  • A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine

22.

NEW PHARMACEUTICAL DEVICE FOR USE IN INTRANASAL ADMINISTRATION

      
Numéro de document 03238847
Statut En instance
Date de dépôt 2022-11-25
Date de disponibilité au public 2023-06-01
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Savmarker, Jonas
  • Ronn, Robert

Abrégé

According to the invention, there is provided a needle-free applicator that is suitable for administering a solid, amorphous, mono-particulate powder composition into a body cavity of a human patient, which cavity includes a mucosal surface, wherein the applicator comprises: (I) an opaque reservoir comprising said powder composition; (ii) an optional actuating means for generating a force upon actuation of the device by a user; and (iii)a dispensing means through which, following said actuation, said powder composition may be dispensed, wherein said powder composition comprises a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof, encapsulated in an amorphous state along with a pharmaceutically-acceptable carrier material; and which powder composition is less than about 4% chemically degraded after storage for: (a) at least about 3 months at 40°C and 75% relative humidity; (b) at least about 18 months at below about 30°C; and/or (c) at least about 18 hours at above about 1 million lux of UV light. Compositions for use in the applicator are preferably made by way of spray drying and the carrier material may include a disaccharide, such as lactose or trehalose, and a maltodextrin, which may be spray-dried together in combination with the active ingredient. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61M 11/02 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux agissant par pression d'air sur les liquides à pulvériser ou vaporiser
  • A61M 15/08 - Dispositifs d'inhalation placés dans le nez
  • A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

23.

PHARMACEUTICAL DEVICE FOR USE IN INTRANASAL ADMINISTRATION

      
Numéro d'application GB2022052983
Numéro de publication 2023/094816
Statut Délivré - en vigueur
Date de dépôt 2022-11-25
Date de publication 2023-06-01
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert

Abrégé

According to the invention, there is provided a needle-free applicator that is suitable for administering a solid, amorphous, mono-particulate powder composition into a body cavity of a human patient, which cavity includes a mucosal surface, wherein the applicator comprises: (I) an opaque reservoir comprising said powder composition; (ii) an optional actuating means for generating a force upon actuation of the device by a user; and (iii)a dispensing means through which, following said actuation, said powder composition may be dispensed, wherein said powder composition comprises a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof, encapsulated in an amorphous state along with a pharmaceutically-acceptable carrier material; and which powder composition is less than about 4% chemically degraded after storage for: (a) at least about 3 months at 40°C and 75% relative humidity; (b) at least about 18 months at below about 30°C; and/or (c) at least about 18 hours at above about 1 million lux of UV light. Compositions for use in the applicator are preferably made by way of spray drying and the carrier material may include a disaccharide, such as lactose or trehalose, and a maltodextrin, which may be spray-dried together in combination with the active ingredient. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.

Classes IPC  ?

  • A61M 15/08 - Dispositifs d'inhalation placés dans le nez
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
  • A61M 11/02 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux agissant par pression d'air sur les liquides à pulvériser ou vaporiser

24.

PHARMACEUTICAL COMPOSITION COMPRISING ATROPINE

      
Numéro d'application GB2022052984
Numéro de publication 2023/094817
Statut Délivré - en vigueur
Date de dépôt 2022-11-25
Date de publication 2023-06-01
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Rönn, Robert
  • Sävmarker, Jonas

Abrégé

According to the invention, there is provided a solid, amorphous mono-particulate powder composition comprising a pharmacologically-effective dosage amount of atropine, or a pharmaceutically-acceptable salt thereof, encapsulated in an amorphous state along with a pharmaceutically-acceptable carrier material. The compositions are preferably made by way of spray drying and the carrier material may include a disaccharide, such as lactose or trehalose, and a maltodextrin, which may be spray- dried together in combination with the active ingredient. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. The compositions are thus particularly useful in the treatment of organophosphorus poisoning.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61M 15/08 - Dispositifs d'inhalation placés dans le nez
  • A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
  • A61P 39/00 - Agents protecteurs généraux ou antipoisons

25.

PHARMACEUTICAL COMPOSITION COMPRISING BIOPHARMACEUTICAL DRUG COMPOUNDS

      
Numéro d'application GB2022052985
Numéro de publication 2023/094818
Statut Délivré - en vigueur
Date de dépôt 2022-11-25
Date de publication 2023-06-01
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert

Abrégé

According to the invention, there is provided a which composition is in the form of an amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one biopharmaceutical drug compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. maltodextrins). Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Powder compositions may be produced by spray-drying the various components together in combination.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61M 15/08 - Dispositifs d'inhalation placés dans le nez
  • A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
  • A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

26.

PHARMACEUTICAL COMPOSITION COMPRISING ADRENALINE

      
Numéro de document 03238850
Statut En instance
Date de dépôt 2022-11-25
Date de disponibilité au public 2023-06-01
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Savmarker, Jonas
  • Ronn, Robert

Abrégé

According to the invention, there is provided aa pharmaceuticaliy-acceptabie composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologicaliy-effective dosage amount of an adrenergic receptor modulator, or a pharmaceuticaliy-acceptabie salt thereof; and (b) a pharmaceuticaliy-acceptabie carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for, for example, transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61M 15/08 - Dispositifs d'inhalation placés dans le nez
  • A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
  • A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

27.

PHARMACEUTICAL COMPOSITION COMPRISING BIOPHARMACEUTICAL DRUG COMPOUNDS

      
Numéro de document 03239053
Statut En instance
Date de dépôt 2022-11-25
Date de disponibilité au public 2023-06-01
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Savmarker, Jonas
  • Ronn, Robert

Abrégé

According to the invention, there is provided a which composition is in the form of an amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one biopharmaceutical drug compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. maltodextrins). Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Powder compositions may be produced by spray-drying the various components together in combination.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
  • A61M 15/08 - Dispositifs d'inhalation placés dans le nez
  • A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

28.

PHARMACEUTICAL COMPOSITION COMPRISING ADRENALINE

      
Numéro d'application GB2022052996
Numéro de publication 2023/094826
Statut Délivré - en vigueur
Date de dépôt 2022-11-25
Date de publication 2023-06-01
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert

Abrégé

According to the invention, there is provided aa pharmaceuticaliy-acceptabie composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologicaliy-effective dosage amount of an adrenergic receptor modulator, or a pharmaceuticaliy-acceptabie salt thereof; and (b) a pharmaceuticaliy-acceptabie carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for, for example, transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61M 15/08 - Dispositifs d'inhalation placés dans le nez
  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
  • A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

29.

Method of controlling depression in subjects treated for opioid dependence

      
Numéro d'application 17363877
Numéro de brevet 11617746
Statut Délivré - en vigueur
Date de dépôt 2021-06-30
Date de la première publication 2023-04-04
Date d'octroi 2023-04-04
Propriétaire OREXO AB (Suède)
Inventeur(s) Sumner, Michael John

Abrégé

The present disclosure is directed to a method of combatting opioid dependence in a subject experiencing a depressive episode. The method comprises treating the subject with an opioid agonist whilst managing their depression or depressive disorder using a step-wise interactive process, particularly where the process involves virtual cognitive behavioral therapy comprising a program for self-treatment. The self-treatment program could be embodied as a mobile medical application.

Classes IPC  ?

  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
  • A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
  • A61P 25/24 - Antidépresseurs
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

30.

MATCORE

      
Numéro de série 97847870
Statut Enregistrée
Date de dépôt 2023-03-20
Date d'enregistrement 2025-04-15
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Downloadable therapeutic medical and counseling content, namely, downloadable electronic data and multimedia files containing text, informational graphics, video and audio, and forms featuring information, instructions, charts, studies, and statistics in the fields of opioid dependence and addiction, treatment of opioid dependence and addiction, health and wellness information related to opioid dependence and addiction, and coaching and consulting for opioid dependence and addiction; downloadable electronic data files and downloadable multimedia files featuring information, instructions, charts, studies, and statistics in the fields of opioid dependence and addiction, treatment of opioid dependence and addiction, health and wellness information related to opioid dependence and addiction, and coaching and consulting for opioid dependence and addiction; downloadable electronic publications, namely, newsletters and written articles for use by medical professionals and patients in the field of opioid dependence, addiction and treatment Providing a website featuring digital therapeutic technology that enables users to treat and receive treatment for opioid dependence and opioid addiction; providing an online non-downloadable digital therapeutic software platform for providing behavioral health services in the nature of coaching, counseling, and advice in the field of opioid dependence, addiction and treatment; providing online non-downloadable computer programs for managing digital therapeutic and medical content in the field of opioid dependence and addiction and the field of treatment of opioid dependence and addiction; providing online non-downloadable software for accessing digital therapeutic resources in the treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for use in facilitating treatment and custom design and management of patient treatment for opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for collecting information and data from and providing addiction information and treatment services to patients; providing a website featuring non-downloadable software for providing telehealth, remote care, and virtual health care services; providing a web hosting digital therapeutic platform for providing behavioral health and medical services in the treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software, namely, an interactive digital healthcare software platform for providing behavioral health services to patients; providing online non-downloadable software to facilitate custom design and provision of addiction counseling, therapy, healthcare and support services in treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for collecting, aggregating and analyzing medical, healthcare and addiction treatment data Therapeutic services, namely, medical counseling, psychological counseling, medical advice, and medical information provided to patients with, and caregivers treating, opioid dependence and opioid addiction; computer-based interactive medical support services, namely, providing online medical advice and medical assistance services relating to the treatment of opioid dependent and addicted patients and their families; therapeutic services, namely, providing medical counseling, psychological counseling, medical advice, and medical information provided to patients and caregivers treating opioid dependence and opioid addiction delivered via non-downloadable software

31.

MATCORE

      
Numéro de série 97817431
Statut Enregistrée
Date de dépôt 2023-03-01
Date d'enregistrement 2025-03-18
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Downloadable therapeutic medical and counseling content, namely, downloadable electronic data and multimedia files containing text, informational graphics, video and audio, and forms featuring information, instructions, charts, studies, and statistics in the fields of opioid dependence and addiction, treatment of opioid dependence and addiction, health and wellness information related to opioid dependence and addiction, and coaching and consulting for opioid dependence and addiction; downloadable electronic data files and downloadable multimedia files featuring information, instructions, charts, studies, and statistics in the fields of opioid dependence and addiction, treatment of opioid dependence and addiction, health and wellness information related to opioid dependence and addiction, and coaching and consulting for opioid dependence and addiction; downloadable electronic publications, namely, newsletters and written articles for use by medical professionals and patients in the field of opioid dependence, addiction and treatment Providing a website featuring digital therapeutic technology that enables users to treat and receive treatment for opioid dependence and opioid addiction; providing an online non-downloadable digital therapeutic software platform for providing behavioral health services in the nature of coaching, counseling, and advice in the field of opioid dependence, addiction and treatment; providing online non-downloadable computer programs for managing digital therapeutic and medical content in the field of opioid dependence and addiction and the field of treatment of opioid dependence and addiction; providing online non-downloadable software for accessing digital therapeutic resources in the treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for use in facilitating treatment and custom design and management of patient treatment for opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for collecting information and data from and providing addiction information and treatment services to patients; providing a website featuring non-downloadable software for providing telehealth, remote care, and virtual health care services; providing a web hosting digital therapeutic platform for providing behavioral health and medical services in the treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software, namely, an interactive digital healthcare software platform for providing behavioral health services to patients; providing online non-downloadable software to facilitate custom design and provision of addiction counseling, therapy, healthcare and support services in treatment of opioid use disorder (OUD), opioid dependence, and opioid addiction; providing online non-downloadable software for collecting, aggregating and analyzing medical, healthcare and addiction treatment data Therapeutic services, namely, medical counseling, psychological counseling, medical advice, and medical information provided to patients with, and caregivers treating, opioid dependence and opioid addiction; computer-based interactive medical support services, namely, providing online medical advice and medical assistance services relating to the treatment of opioid dependent and addicted patients and their families; therapeutic services, namely, providing medical counseling, psychological counseling, medical advice, and medical information provided to patients and caregivers treating opioid dependence and opioid addiction delivered via non-downloadable software

32.

Pharmaceutical composition for drug delivery

      
Numéro d'application 17540929
Numéro de brevet 11737980
Statut Délivré - en vigueur
Date de dépôt 2021-12-02
Date de la première publication 2022-03-24
Date d'octroi 2023-08-29
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert
  • Fischer, Andreas

Abrégé

(b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Compositions are suitable for, for example, transmucosal drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. cyclodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

33.

Pharmaceutical composition for nasal delivery

      
Numéro d'application 17172635
Numéro de brevet 11883392
Statut Délivré - en vigueur
Date de dépôt 2021-02-10
Date de la première publication 2021-12-30
Date d'octroi 2024-01-30
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert
  • Fischer, Andreas

Abrégé

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine

34.

MODIA

      
Numéro de série 79330810
Statut Enregistrée
Date de dépôt 2021-12-07
Date d'enregistrement 2023-08-29
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 09 - Appareils et instruments scientifiques et électriques

Produits et services

Downloadable, printable therapeutic medical and counseling content, namely, downloadable files containing printable text and information graphics, downloadable forms, downloadable electronic data files and downloadable multimedia files containing text and graphics all featuring information, instructions, charts, studies, data in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, related health and wellness, and coaching and consulting information therefor; downloadable electronic publications, namely, downloadable newsletters and written articles for use by medical professionals and patients in the field of opioid dependence, addiction and treatment

35.

amorphOX

      
Numéro d'application 018608765
Statut Enregistrée
Date de dépôt 2021-11-25
Date d'enregistrement 2022-03-31
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

Pharmaceutical preparations. Development of pharmaceutical preparations; research and development in the pharmaceutical fields; research and development of drug delivery platforms.

36.

modia

      
Numéro d'application 1628752
Statut Enregistrée
Date de dépôt 2021-05-05
Date d'enregistrement 2021-05-05
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Downloadable, printable therapeutic medical and counseling content, namely, information, forms, instructions, charts, studies, data and related coaching and advice in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of field of opioid dependence, addiction and treatment. Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction. Providing a website featuring digital therapeutic technology for treating opioid dependence and opioid addiction (terms considered too vague by the International Bureau - rule 13 (2) (b) of the Regulations); providing an online digital therapeutic platform for providing behavioral health services, namely coaching, counseling, advice in the field of opioid dependence, addiction and treatment (terms considered too vague by the International Bureau - rule 13 (2) (b) of the Regulations); conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely computer-based interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction. Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; computer-based interactive medical support services, namely, providing online medical advice and assisting with treatment of opioid dependent and addicted patients and their families.

37.

NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY

      
Numéro de document 03178769
Statut En instance
Date de dépôt 2021-05-18
Date de disponibilité au public 2021-11-25
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Savmarker, Jonas
  • Ronn, Robert
  • Fischer, Andreas

Abrégé

According to the invention, there is provided a pharmaceutica!!y-acceptab!e composition which is preferably in the form of a spray-dried powder comprising a mixture of: (a) a pharmaco!ogica!!y-effective dosage amount of at least one pharmaceutically- active compound; and (b) a pharmaceutioai!y-acceptab!e carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Compositions are suitable for, for example, transmucossl drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically- acceptab!e carriers in this regard include lactose or trehalose and dextrins (e.g. cydodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more aikyi saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
  • A61K 38/00 - Préparations médicinales contenant des peptides
  • A61K 38/095 - Oxytocines Vasopressines Peptides apparentés
  • A61P 13/00 - Médicaments pour le traitement des troubles du système urinaire

38.

NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY

      
Numéro d'application GB2021051191
Numéro de publication 2021/234366
Statut Délivré - en vigueur
Date de dépôt 2021-05-18
Date de publication 2021-11-25
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert
  • Fischer, Andreas

Abrégé

According to the invention, there is provided a pharmaceutica!!y-acceptab!e composition which is preferably in the form of a spray-dried powder comprising a mixture of: (a) a pharmaco!ogica!!y-effective dosage amount of at least one pharmaceutically- active compound; and (b) a pharmaceutioai!y-acceptab!e carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Compositions are suitable for, for example, transmucossl drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically- acceptab!e carriers in this regard include lactose or trehalose and dextrins (e.g. cydodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more aikyi saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
  • A61K 38/095 - Oxytocines Vasopressines Peptides apparentés
  • A61P 13/00 - Médicaments pour le traitement des troubles du système urinaire
  • A61K 38/00 - Préparations médicinales contenant des peptides

39.

AMORPHOX

      
Numéro d'application 018607645
Statut Enregistrée
Date de dépôt 2021-11-23
Date d'enregistrement 2022-03-31
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

Pharmaceutical preparations. Development of pharmaceutical preparations; research and development in the pharmaceutical fields; research and development of drug delivery platforms.

40.

MODIA

      
Numéro d'application 214941500
Statut Enregistrée
Date de dépôt 2021-05-05
Date d'enregistrement 2024-02-05
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

(1) Downloadable printable therapeutic medical and counseling content, namely, medical information, medical forms, instruction manuals, medical information charts, studies, data and related coaching and advice in form of newsletters, periodicals, pamphlets, research reports and brochures all in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of field of opioid dependence, addiction and treatment. (1) Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields via computer software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction. (2) Providing a website featuring digital therapeutic technology for treating opioid dependence and opioid addiction; providing an online digital therapeutic platform for providing behavioral health services, namely coaching, counseling, advice in the field of opioid dependence, addiction and treatment; conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely computer-based interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction. (3) Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; computer-based interactive medical support services, namely, providing online medical advice and assisting with treatment of opioid dependent and addicted patients and their families.

41.

MODIA

      
Numéro de série 79326722
Statut Enregistrée
Date de dépôt 2021-05-05
Date d'enregistrement 2022-07-05
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Downloadable therapeutic medical and counseling content, namely, downloadable written and graphic materials, downloadable forms, downloadable electronic data files, downloadable multimedia files featuring information, instructions, charts, studies, data in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, related health and wellness, and coaching and consulting information therefor; downloadable electronic publications, namely, downloadable newsletters and articles for use by medical professionals and patients in the field of field of opioid dependence, addiction and treatment Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction Providing a website featuring digital therapeutic technology for the treatment of opioid dependence and opioid addiction; providing an online non-downloadable digital therapeutic software platform for providing behavioral health services in the nature of coaching, counseling, advice in the field of opioid dependence, addiction and treatment; conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely, technological research and design of computer software for interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; computer-based interactive medical support services, namely, providing online medical advice and medical assistance services relating to the treatment of opioid dependent and addicted patients and their families

42.

MODIA

      
Numéro de série 79312057
Statut Enregistrée
Date de dépôt 2021-05-05
Date d'enregistrement 2022-06-28
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 41 - Éducation, divertissements, activités sportives et culturelles

Produits et services

Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction

43.

MODIA

      
Numéro d'application 1580019
Statut Enregistrée
Date de dépôt 2020-12-01
Date d'enregistrement 2020-12-01
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Downloadable, printable therapeutic medical and counseling content, namely, information, forms, instructions, charts, studies, data and related coaching and advice in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of opioid dependence, addiction and treatment. Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction. Providing a website featuring digital therapeutic technology for treating opioid dependence and opioid addiction; conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely computer-based interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction. Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; providing an online digital therapeutic platform for providing behavioral health services, namely coaching, counseling, advice in the field of opioid dependence, addiction and treatment; computer-based interactive medical support services, namely, providing online medical advice and assisting with treatment of opioid dependent and addicted patients and their families.

44.

PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERY

      
Numéro d'application GB2020051207
Numéro de publication 2021/005325
Statut Délivré - en vigueur
Date de dépôt 2020-05-18
Date de publication 2021-01-14
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert
  • Fischer, Andreas

Abrégé

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically- effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. Said compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. Said compositions and applicators may be employed in the treatment of opioid overdose in subjects.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine

45.

PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERY

      
Numéro de document 03145965
Statut En instance
Date de dépôt 2020-05-18
Date de disponibilité au public 2021-01-14
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Savmarker, Jonas
  • Ronn, Robert
  • Fischer, Andreas

Abrégé

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically- effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. Said compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. Said compositions and applicators may be employed in the treatment of opioid overdose in subjects.

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
  • A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
  • A61K 47/40 - CyclodextrinesLeurs dérivés
  • A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés

46.

Pharmaceutical composition for nasal delivery

      
Numéro d'application 16939660
Numéro de brevet 10898480
Statut Délivré - en vigueur
Date de dépôt 2020-07-27
Date de la première publication 2021-01-14
Date d'octroi 2021-01-26
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert

Abrégé

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
  • A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

47.

MODIA

      
Numéro d'application 209077600
Statut Enregistrée
Date de dépôt 2020-12-01
Date d'enregistrement 2023-11-01
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

(1) Downloadable, therapeutic medical and counseling information in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness; downloadable therapeutic medical and counseling studies in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness in the form of charts; downloadable therapeutic medical coaching and advice in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness in the form of instructions, charts and studies; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of opioid dependence, addiction and treatment; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of opioid dependence, addiction and treatment (1) Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction (2) Providing a website featuring digital therapeutic technology for treating opioid dependence and opioid addiction; conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely computer-based interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction (3) Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; providing an online digital therapeutic platform for providing behavioral health services, namely coaching, counseling, advice in the field of opioid dependence, addiction and treatment; Computer-based interactive medical support services, namely, providing online medical advice and assisting with treatment of opioid dependent and addicted patients and their families

48.

modia

      
Numéro d'application 018337756
Statut Enregistrée
Date de dépôt 2020-11-12
Date d'enregistrement 2021-05-13
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Downloadable, printable therapeutic medical and counseling content, namely, information, forms, instructions, charts, studies, data and related coaching and advice in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of field of opioid dependence, addiction and treatment. Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction. Providing a website featuring digital therapeutic technology for treating opioid dependence and opioid addiction; providing an online digital therapeutic platform for providing behavioral health services, namely coaching, counseling, advice in the field of opioid dependence, addiction and treatment; conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely computer-based interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction. Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; Computer-based interactive medical support services, namely, providing online medical advice and assisting with treatment of opioid dependent and addicted patients and their families.

49.

MODIA

      
Numéro d'application 018337749
Statut Enregistrée
Date de dépôt 2020-11-12
Date d'enregistrement 2021-05-13
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Downloadable, printable therapeutic medical and counseling content, namely, information, forms, instructions, charts, studies, data and related coaching and advice in the field of opioid dependence and addiction, treatment of opioid dependence and addiction, and related health and wellness; electronic publications, namely, newsletters and articles for use by medical professionals and patients in the field of field of opioid dependence, addiction and treatment. Providing of training and further education in the nature of virtual lectures in the field of medicine, health and wellness for users in the medical fields with the aid of software; further education in the nature of courses, webinars, seminars, and workshops in the field of medicine, health and wellness for patients suffering from opioid addiction and for medical personnel specialized on the treatment of opioid addiction. Providing a website featuring digital therapeutic technology for treating opioid dependence and opioid addiction; providing an online digital therapeutic platform for providing behavioral health services, namely coaching, counseling, advice in the field of opioid dependence, addiction and treatment; conducting medical and scientific and technological research in the field of opioid dependence and opioid addiction; conducting technological research and design of digital therapeutics, namely computer-based interactive and online psychological intervention and counseling in the field of opioid dependence and addiction; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of opioid dependence and addiction and the treatment of opioid dependence and addiction. Therapeutic services, namely, medical counselling, psychological counselling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; Computer-based interactive medical support services, namely, providing online medical advice and assisting with treatment of opioid dependent and addicted patients and their families.

50.

PHARMACEUTICAL COMPOSITIONS

      
Numéro d'application GB2020050892
Numéro de publication 2020/201768
Statut Délivré - en vigueur
Date de dépôt 2020-04-03
Date de publication 2020-10-08
Propriétaire OREXO AB (Suède)
Inventeur(s) Fischer, Andreas

Abrégé

8-228-22 fatty acid, such as oleic acid or myristic acid. The dosage forms are useful in the treatment of a variety of psychotic conditions, such as schizophrenia, bipolar disorder and ADHD.

Classes IPC  ?

  • A61K 9/107 - Émulsions
  • A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
  • A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat

51.

NEW PHARMACEUTICAL COMPOSITIONS

      
Numéro d'application GB2020050896
Numéro de publication 2020/201771
Statut Délivré - en vigueur
Date de dépôt 2020-04-03
Date de publication 2020-10-08
Propriétaire OREXO AB (Suède)
Inventeur(s) Fischer, Andreas

Abrégé

There are provided solid, pharmaceutically-acceptable compositions suitable for peroral administration to the gastrointestinal tract, in which (a) an opioid analgesic and (b) a sucrose ester with a hydrophilic-lipophilic balance value of between 6 and 20 are both dissolved and/or dispersed in a C12-22 fatty acid, which fatty acid is a solid at about 37°C, such as myristic acid, lauric acid, palmitic acid, stearic acid, arachidic acid and behenic acid. The dosage forms are abuse-resistant and are useful in the treatment of inter alia opioid dependency/addiction and/or pain.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

52.

Pharmaceutical composition for nasal delivery

      
Numéro d'application 16876468
Numéro de brevet 10729687
Statut Délivré - en vigueur
Date de dépôt 2020-05-18
Date de la première publication 2020-08-04
Date d'octroi 2020-08-04
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert
  • Fischer, Andreas

Abrégé

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

Classes IPC  ?

  • A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

53.

MODIA

      
Numéro de série 90003373
Statut Enregistrée
Date de dépôt 2020-06-16
Date d'enregistrement 2022-03-15
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Therapeutic services, namely, medical counseling, psychological counseling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction; therapeutic services, namely, medical counseling, psychological counseling, medical advice and medical information provided to patients with, and care givers treating, opioid dependence and opioid addiction via an online digital platform

54.

Pharmaceutical composition for nasal delivery

      
Numéro d'application 16506023
Numéro de brevet 10653690
Statut Délivré - en vigueur
Date de dépôt 2019-07-09
Date de la première publication 2020-05-19
Date d'octroi 2020-05-19
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Sävmarker, Jonas
  • Rönn, Robert
  • Fischer, Andreas

Abrégé

There is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist. The pharmaceutical composition includes a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The pharmaceutical composition is preferably in the form of a powder produced by spray-drying, which is subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. The pharmaceutical composition may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

Classes IPC  ?

  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

55.

zubsolv

      
Numéro d'application 1517245
Statut Enregistrée
Date de dépôt 2019-11-29
Date d'enregistrement 2019-11-29
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 35 - Publicité; Affaires commerciales
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Advertising; advertising of pharmaceutical products; demonstration of goods for promotional purposes; distribution of samples; provision of commercial information. Educational services, namely, providing instructional courses and seminars in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery; providing training in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery. Medical services in the nature of medical support services, namely, medical counseling, psychological counseling, medical advice and medical information provided to patients with dependence and opioid addiction and to their care givers.

56.

ZUBSOLV

      
Numéro d'application 1517202
Statut Enregistrée
Date de dépôt 2019-11-29
Date d'enregistrement 2019-11-29
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 35 - Publicité; Affaires commerciales
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Advertising; advertising of pharmaceutical products; demonstration of goods for promotional purposes; distribution of samples; provision of commercial information. Educational services, namely, providing instructional courses and seminars in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery; providing training in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery. Medical services in the nature of medical support services, namely, medical counseling, psychological counseling, medical advice and medical information provided to patients with dependence and opioid addiction and to their care givers.

57.

ZUBSOLV

      
Numéro d'application 018091156
Statut Enregistrée
Date de dépôt 2019-07-04
Date d'enregistrement 2019-11-02
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 35 - Publicité; Affaires commerciales
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Advertising; advertising of pharmaceutical products; demonstration of goods for promotional purposes; distribution of samples; provision of commercial information. Educational services, namely, providing instructional courses and seminars in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery; providing training in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery. Medical services in the nature of medical support services, namely, medical counseling, psychological counseling, medical advice and medical information provided to patients with dependence and opioid addiction and to their care givers.

58.

zubsolv

      
Numéro d'application 018091154
Statut Enregistrée
Date de dépôt 2019-07-04
Date d'enregistrement 2020-01-09
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 35 - Publicité; Affaires commerciales
  • 41 - Éducation, divertissements, activités sportives et culturelles
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Advertising; advertising of pharmaceutical products; demonstration of goods for promotional purposes; distribution of samples; provision of commercial information. Educational services, namely, providing instructional courses and seminars in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery; providing training in the field of opioid dependence and opioid addiction to enable further self-directed education and recovery. Medical services in the nature of medical support services, namely, medical counseling, psychological counseling, medical advice and medical information provided to patients with dependence and opioid addiction and to their care givers.

59.

NEW PHARMACEUTICAL COMPOSITIONS

      
Numéro d'application GB2018052792
Numéro de publication 2019/064026
Statut Délivré - en vigueur
Date de dépôt 2018-09-28
Date de publication 2019-04-04
Propriétaire OREXO AB (Suède)
Inventeur(s) Fischer, Andreas

Abrégé

8-20 inter alia inter alia opioid dependency/addiction and/or pain.

Classes IPC  ?

60.

ZUBSOLV

      
Numéro d'application 191928200
Statut Enregistrée
Date de dépôt 2018-09-11
Date d'enregistrement 2021-09-28
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

(1) Pharmaceutical preparations for human use, namely, preparations for the treatment of opioid dependence, preparations for the treatment of drug addiction, and opiate antagonist preparations for the treatment of opioid dependence and addiction; pain relief preparations and pain killers for human use

61.

ZUBSOLV

      
Numéro d'application 191928300
Statut Enregistrée
Date de dépôt 2018-09-11
Date d'enregistrement 2021-09-28
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

(1) Pharmaceutical preparations for human use, namely, preparations for the treatment of opioid dependence, preparations for the treatment of drug addiction, and opiate antagonist preparations for the treatment of opioid dependence and addiction; pain relief preparations and pain killers for human use

62.

OREXO

      
Numéro d'application 1286384
Statut Enregistrée
Date de dépôt 2015-12-17
Date d'enregistrement 2015-12-17
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Pharmaceutical preparations, namely for the treatment of heartburn, migraine, insomnia, urinary incontinence, asthma, rhinitis, oesteoarthrosis, inflammatory diseases, chronic obstructive pulmonary disease (COPD) opioid dependence, cancer as well as pain relief and pain killers, to the exclusion of anti-infectious products and antibiotics. Clinical research and professional expertise relating thereto. Pharmaceutical services and professional expertise relating thereto. Licensing within the field of medicines.

63.

OREXO

      
Numéro de série 79181944
Statut Enregistrée
Date de dépôt 2015-12-17
Date d'enregistrement 2017-11-28
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Pharmaceutical preparations, namely, for the treatment of [ heartburn, migraine, insomnia, urinary incontinence, asthma, rhinitis, oesteoarthrosis, inflammatory diseases, chronic obstructive pulmonary disease (COPD) ] opioid dependence [ , cancer as well as pain relief and pain killers, to the exclusion of anti-infectious products and antibiotics ] Conducting basic and clinical research in the field of medicine, pharmacology and testing of pharmaceuticals and consultation related thereto Pharmaceutical advice Licensing of intellectual property within the field of medicines

64.

NEW SUFENTANIL COMPOSITION FOR THE TREATMENT OF ACUTE PAIN

      
Numéro d'application GB2013051128
Numéro de publication 2013/164617
Statut Délivré - en vigueur
Date de dépôt 2013-05-01
Date de publication 2013-11-07
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Petterson, Anders
  • Mogensen, Sofia
  • Johansson, Barbro
  • Schwan, Emil

Abrégé

There is provided pharmaceutical compositions for the treatment of pain e.g. breakthrough pain which compositions comprise a mixture comprising: (a) microparticles of sufentanil, or a pharmaceutically acceptable salt thereof, which microparticles are presented on the surfaces of larger carrier particles; (b) a water-soluble weak base; and (c) a compound which is a weak acid, which acid is presented in intimate mixture with the microparticles of sufentanil or salt thereof. The composition may further comprise a disintegrant. The acid is preferably citric acid.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène

65.

NEW ALFENTANIL COMPOSITION FOR THE TREATMENT OF ACUTE PAIN

      
Numéro d'application GB2013051131
Numéro de publication 2013/164620
Statut Délivré - en vigueur
Date de dépôt 2013-05-01
Date de publication 2013-11-07
Propriétaire
  • OREXO AB (Suède)
  • MCNEENEY, Stephen Phillip (Royaume‑Uni)
Inventeur(s)
  • Pettersson, Anders
  • Schwan, Emil
  • Johansson, Barbro

Abrégé

There is provided pharmaceutical compositions for the treatment of pain e.g. short-term pain, which compositions comprise a mixture comprising: (a) microparticles of alfentanil, or a pharmaceutically acceptable salt thereof, which microparticles are presented on the surfaces of larger carrier particles; (b) a water-soluble weak base; and (c) a compound which is a weak acid, which acid is presented in intimate mixture with the microparticles of alfentanil or salt thereof. The composition may further comprise a disintegrant. The acid is preferably citric acid.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone

66.

zubsolv

      
Numéro d'application 1162402
Statut Enregistrée
Date de dépôt 2013-04-15
Date d'enregistrement 2013-04-15
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations for human use for the treatment of opioid dependence; pain relief preparations and pain killers for human use.

67.

NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE

      
Numéro de document 02834327
Statut Délivré - en vigueur
Date de dépôt 2012-09-18
Date de disponibilité au public 2013-03-28
Date d'octroi 2017-05-30
Propriétaire OREXO AB (Suède)
Inventeur(s) Fischer, Andreas

Abrégé

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly- acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine

68.

NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE

      
Numéro d'application GB2012052303
Numéro de publication 2013/041851
Statut Délivré - en vigueur
Date de dépôt 2012-09-18
Date de publication 2013-03-28
Propriétaire OREXO AB (Suède)
Inventeur(s) Fischer, Andreas

Abrégé

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly- acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine

69.

ZUBSOLV

      
Numéro d'application 011565629
Statut Enregistrée
Date de dépôt 2013-02-12
Date d'enregistrement 2013-07-04
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations for human use for the treatment of opioid dependence; pain relief preparations and pain killers for human use.

70.

ZUBSOLV

      
Numéro d'application 1112789
Statut Enregistrée
Date de dépôt 2012-03-29
Date d'enregistrement 2012-03-29
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations for human use.

71.

ZUBSOLV

      
Numéro d'application 010760321
Statut Enregistrée
Date de dépôt 2012-03-27
Date d'enregistrement 2012-08-09
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical preparations for human use.

72.

A TRANSDERMAL DRUG ADMINISTRATION DEVICE

      
Numéro d'application GB2011051658
Numéro de publication 2012/032337
Statut Délivré - en vigueur
Date de dépôt 2011-09-05
Date de publication 2012-03-15
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Engqvist, Håkan
  • Bredenberg, Susanne
  • Pettersson, Anders
  • Lundqvist, Thomas
  • Dahlgren, Anna
  • Sågström, Anders

Abrégé

A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.

Classes IPC  ?

  • A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
  • A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 9/70 - Bases pour bande, feuille ou filament

73.

OREXO

      
Numéro d'application 010217594
Statut Enregistrée
Date de dépôt 2011-08-25
Date d'enregistrement 2012-03-16
Propriétaire Orexo AB (Suède)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
  • 45 - Services juridiques; services de sécurité; services personnels pour individus

Produits et services

Pharmaceutical preparations, namely for the treatment of heartburn, migraine, insomnia, urinary incontinence, asthma, rhinitis, oesteoarthrosis, inflammatory diseases, chronic obstructive pulmonary disease (COPD) opioid dependence, cancer as well as pain relief and pain killers, to the exclusion of anti-infectious products and antibiotics. Clinical research and professional expertise relating thereto. Pharmaceutical services and professional expertise relating thereto. Licensing within the field of medicines.

74.

NEW PHARMACEUTICAL DOSAGE FORM FOR THE TREATMENT OF GASTRIC ACID-RELATED DISORDERS

      
Numéro d'application GB2010002337
Numéro de publication 2011/080502
Statut Délivré - en vigueur
Date de dépôt 2010-12-24
Date de publication 2011-07-07
Propriétaire OREXO AB (Suède)
Inventeur(s) Fischer, Andreas

Abrégé

According to the invention there is provided a pharmaceutical composition for peroral administration to the gastrointestinal tract comprising: (i) a plurality of granules comprising a pharmacologically effective amount of a micronised H2 receptor antagonist or a pharmaceutically acceptable salt thereof granulated together with a disintegrant; and (ii) a pharmaceutically acceptable carrier, wherein the granules (i) are distributed homogeneously within the carrier (ii). The compositions of the invention are particularly useful in the treatment of gastric acid secretion-related disorders, such as gastro-esophageal reflux disease.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 31/426 - 1,3-Thiazoles
  • A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
  • A61K 9/50 - Microcapsules
  • A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

75.

NEW PHARMACEUTICAL DOSAGE FORM FOR THE TREATMENT OF GASTRIC ACID-RELATED DISORDERS

      
Numéro d'application GB2010002335
Numéro de publication 2011/080500
Statut Délivré - en vigueur
Date de dépôt 2010-12-24
Date de publication 2011-07-07
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Fischer, Andreas
  • Schwan, Emil

Abrégé

According to the invention there is provided a single unit oral dosage form comprising: (a) a first component comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof and an enteric substance positioned to protect the proton pump inhibitor from the acidic environment of the stomach; (b) a second component comprising an H2 receptor antagonist or a pharmaceutically acceptable salt thereof; and (c) a physical and/or chemical barrier located between the first and second components, and preventing said components from interacting with each other. The dosage forms of the invention are particularly useful in the treatment of gastric acid secretion-related disorders, such as gastro-esophageal reflux disease.

Classes IPC  ?

  • A61K 9/20 - Pilules, pastilles ou comprimés
  • A61K 31/426 - 1,3-Thiazoles
  • A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole

76.

COMPOSITION FOR SUSTAINED DRUG DELIVERY COMPRISING GEOPOLYMERIC BINDER

      
Numéro d'application GB2010000910
Numéro de publication 2010/128300
Statut Délivré - en vigueur
Date de dépôt 2010-05-07
Date de publication 2010-11-11
Propriétaire OREXO AB (Suède)
Inventeur(s) Engqvist, Häkan

Abrégé

The present invention relates to a sustained release medical composition comprising an active pharmaceutical ingredient and a geopolymeric binder. Preferably the active pharmaceutical ingredient is combined with the geopolymeric binder during the formation of that binder.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61K 47/02 - Composés inorganiques
  • A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl

77.

ABUSE RESISTANT FORMULATION

      
Numéro d'application GB2010000374
Numéro de publication 2010/100414
Statut Délivré - en vigueur
Date de dépôt 2010-03-02
Date de publication 2010-09-10
Propriétaire OREXO AB (Suède)
Inventeur(s)
  • Bredenberg, Susanne
  • Dahlgren, Anna
  • Sägström, Anders
  • Engqvist, Hakan

Abrégé

There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.

Classes IPC  ?

  • A61K 9/16 - AgglomérésGranulésMicrobilles
  • A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
  • A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
  • A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl

78.

ZUBLINOX

      
Numéro d'application 985957
Statut Enregistrée
Date de dépôt 2008-09-18
Date d'enregistrement 2008-09-18
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants.

79.

Pharmaceutical formulations useful in the treatment of insomnia

      
Numéro d'application 11666361
Numéro de brevet 09265720
Statut Délivré - en vigueur
Date de dépôt 2005-10-26
Date de la première publication 2008-12-18
Date d'octroi 2016-02-23
Propriétaire Orexo AB (Suède)
Inventeur(s)
  • Pettersson, Anders
  • Nyström, Christer
  • Bredenberg, Susanne

Abrégé

There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.

Classes IPC  ?

  • A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
  • C07D 471/04 - Systèmes condensés en ortho
  • A61P 25/20 - HypnotiquesSédatifs
  • A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés

80.

PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCUSAL DELIVERY OF A THERAPEUTICALLY ACTIVE AGENT ON THE BASIS OF SUBMICRON PARTICLES

      
Numéro d'application GB2007050766
Numéro de publication 2008/075102
Statut Délivré - en vigueur
Date de dépôt 2007-12-19
Date de publication 2008-06-26
Propriétaire PHARMAKODEX LIMITED (Royaume‑Uni)
Inventeur(s) Staniforth, John Nicholas

Abrégé

The present invention relates to improved compositions for transmucosal administration, the compositions enabling rapid and efficient uptake of a therapeutically active agent to provide a rapid, effectively durable, predictable and consistent therapeutic effect. In particular, the compositions are intended for buccal and/or sublingual delivery. The invention is particularly suitable for administering therapeutically active agents which have an effect on the central nervous system and even more particularly where rapid onset of this effect is desired or beneficial. The invention is also particularly suitable for administering active agents in low solubility base or acid forms.

Classes IPC  ?

  • A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
  • A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques

81.

NEW NON-ABUSABLE PHARMACEUTICAL COMPOSITION COMPRISING OPIOIDS

      
Numéro d'application GB2007004627
Numéro de publication 2008/068471
Statut Délivré - en vigueur
Date de dépôt 2007-12-03
Date de publication 2008-06-12
Propriétaire OREXO AB (Suède)
Inventeur(s) Pettersson, Anders

Abrégé

There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.

Classes IPC  ?

82.

SUBLINOX

      
Numéro d'application 906999
Statut Enregistrée
Date de dépôt 2006-08-18
Date d'enregistrement 2006-08-18
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use; food for babies; plasters, materials for dressing; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides.

83.

SUBLINOX

      
Numéro d'application 131361200
Statut Enregistrée
Date de dépôt 2006-08-21
Date d'enregistrement 2012-02-02
Propriétaire Orexo AB (Suède)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

(1) Pharmaceutical preparations for the prevention and/or treatment of: central nervous system diseases and disorders, namely, insomnia.